Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Jefferies Virtual Healthcare Conference 2021

20 slides from Evofem Biosciences's conference presentation, Jun 4, 2021

  1. Slide 1: Revolutionizing Women's Sexual and Reproductive Health

    1© 2021 Evofem Biosciences, Inc. For investor discussions only.For investor discussions only. Saundra Pelletier, CEO Revolutionizing Women’s Sexual and Reproductive Health NASDAQ: EVFM Jefferies Virtual Healthcare Conference 2021 June 4, 2021

  2. Slide 2: Forward-Looking Statements

    2© 2021 Evofem Biosciences, Inc. For investor discussions only.For investor discussions only. Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases,

  3. Slide 3: Evofem Biosciences (Nasdaq: EVFM)

    3© 2021 Evofem Biosciences, Inc. For investor discussions only. Evofem Biosciences (Nasdaq: EVFM) Commercial-stage biopharmaceutical company targeting large markets with significant unmet need First commercial product launched September 2020 o FDA-approved hormone-free, on-demand prescription contra

  4. Slide 4: Phexxi: An Innovative Prescription Contraceptive

    4© 2021 Evofem Biosciences, Inc. For investor discussions only. Phexxi: An Innovative Prescription Contraceptive • FDA-approved for the prevention of pregnancy • Hormone-free • Applied 0-60 minutes before sex

  5. Slide 5: Contraceptive Commercial Opportunity

    5© 2021 Evofem Biosciences, Inc. For investor discussions only. 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14. 2. Example market penetration in segment 3. Gross value of Phexxi user = $267.50 WAC x 7 annual refi

  6. Slide 6: Focus on Phexxi Growth

    6© 2021 Evofem Biosciences, Inc. For investor discussions only. “Best in Class” Sales Team • 70 women’s health sales reps and regional managers • Targeting: o ~3,500 accounts o Top 12K HCPs are highest prescribers of contraception Direct-to-Consumer (DTC) Marketing • Record-setting campaign launched

  7. Slide 7: 'Get Phexxi' Moves the Market!

    7© 2021 Evofem Biosciences, Inc. For investor discussions only. KEY DATA METRICS 411.4M Video views1 12X Increase in organic search traffic2 5X Increase in High Value Action Rate2 Contraception is all about compromises. GET PAST THE COMPROMISES AND GET PHEXXI CONTRACEPTION COMES WITH ITS COMPROMISES

  8. Slide 8: Phexxi - the #1 Followed Contraceptive Brand in the U.S.

    8© 2021 Evofem Biosciences, Inc. For investor discussions only. Phexxi - the #1 Followed Contraceptive Brand in the U.S. 8 • 18+ consumer influencers to date • 35+ content pieces on Instagram and Facebook • Most followed Rx contraceptive brand on Instagram • ~7M impressions • ~4.65M reach • ~170K en

  9. Slide 9: Overheard: What Women are Saying About Phexxi

    9© 2021 Evofem Biosciences, Inc. For investor discussions only. Overheard: What Women are Saying About Phexxi 9

  10. Slide 10: Growth in Rx and Prescriber Base

    10© 2021 Evofem Biosciences, Inc. For investor discussions only. Growth in Rx and Prescriber Base 379 3,855 8,681 4,364 - 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 10,000 Q3 2020 Q4 2020 Q1 2021 Q2 2021 (QTD) TOTAL DISPENSED PRESCRIPTIONS BY QUARTER Source: IQVIA (including Knipper) mont

  11. Slide 11: Phexxi Sample Program

    11© 2021 Evofem Biosciences, Inc. For investor discussions only. Phexxi Sample Program • Launched May 2021 • Three Phexxi applicators per sample • Enables women to begin using Phexxi while prior authorization is processed

  12. Slide 12: Phexxi for Cancer Patients

    12© 2021 Evofem Biosciences, Inc. For investor discussions only. Phexxi for Cancer Patients • ~800,000 new cases of cancer reported annually among women1 • Many women with cancer are contraindicated to hormones oPhexxi uniquely offers hormone-free, non-invasive prescription contraception • NCODA col

  13. Slide 13: Key Initiatives and Anticipated Milestones

    13© 2021 Evofem Biosciences, Inc. For investor discussions only. KEY INITIATIVES AND ANTICIPATED MILESTONES

  14. Slide 14: Increase Access to Phexxi through ACA

    14© 2021 Evofem Biosciences, Inc. For investor discussions only. 1. Increase Access to Phexxi through ACA • Phexxi coverage for 55% of commercial lives and 100% of Medicaid lives • Affordable Care Act (ACA) currently mandates 18 specific methods of contraception be covered without any out-of-pocket

  15. Slide 15: Partner for Ex-U.S. Commercialization

    15© 2021 Evofem Biosciences, Inc. For investor discussions only. 2. Partner for ex-U.S. Commercialization • Discussions underway with potential partners for commercialization of Phexxi in multiple international markets • Anticipated structure: upfront payment, milestone payment(s) and royalties on f

  16. Slide 16: Successfully Develop EVO100 for STI Prevention

    16© 2021 Evofem Biosciences, Inc. For investor discussions only. 3. Successfully Develop EVO100 for STI Prevention • Target indications: prevention of urogenital chlamydia and gonorrhea in women • Positive results of Phase 2B/3 ‘AMPREVENCE’ trial1 o Statistically significant o Clinically meaningful

  17. Slide 17: STI Prevention: Condoms Alone are not the Solution

    17© 2021 Evofem Biosciences, Inc. For investor discussions only. GLOBAL • 215M new infections in 20161 o Chlamydia: 127M2 o Gonorrhea: ~87M3 UNITED STATES • Infection rates increased for 6th consecutive year despite availability of condoms for STI prevention4 ~25% of women aged 15 - 44 use condoms5

  18. Slide 18: U.S. Opportunity: Prevention of Chlamydia & Gonorrhea

    18© 2021 Evofem Biosciences, Inc. For investor discussions only. U.S. Opportunity: Prevention of Chlamydia & Gonorrhea LABEL EXPANSION COULD GROW PHEXXI / EVO100 USER BASE BY 1.1M WOMEN (PEAK)1 1. Source: Integrated Insight Lifecycle Management Market Research – January 2017. Assumes Affordable Care

  19. Slide 19: Breaking the Hormone Glass Ceiling

    19© 2021 Evofem Biosciences, Inc. For investor discussions only. Breaking the Hormone Glass Ceiling • Phexxi: hormone-free prescription contraception women control and use only when needed o$2.4Bn peak U.S. market opportunity • Aggressively pursuing ACA strategy • Advancing ex-U.S. partnership discu

  20. Slide 20: 20©

    20© 2021 Evofem Biosciences, Inc. For investor discussions only. © 2021 Evofem Biosciences, Inc.

Evofem Biosciences — Jefferies Virtual Healthcare Conference 2021 on 6ix